Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Free Trial Request
Subscribe
Advertising
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Compliance

FDA Wants Compounding Authority Clarified, Congress Not So Sure It’s Necessary

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner Hamburg asks for more power over non-traditional compounding to better regulate companies like the New England Compounding Center, but several House members say it looks like the agency already has the authority it needs.

Table

View full table

Advertisement

Related Content

Pink Sheet
FDA Drugs Field Staff May Be Based In Four Offices After Realignment
Pink Sheet
FDA Drugs Field Staff May Be Based In Four Offices After Realignment
Pink Sheet
Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
Pink Sheet
The Atypical Commissioner Turns Out Well: Hamburg Receives Mostly Fond Farewell
Pink Sheet
FDA Power v. State Laws: Compounders Want Clarity On Office Use
Pink Sheet
Early Thanksgiving Present: Obama Signs Compounding/Track And Trace Bill
Pink Sheet
Compounding Law: How Many “Outsourcing Facilities” Will Emerge?
Pink Sheet
Compounding Hearings Are First Step In Creating Active Legislative Ingredients
Pink Sheet
FDA’s Compounding Oversight: What Price Safety?
Pink Sheet
GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification

Topics

What to read next

Advertisement
Tags:
BioPharmaceutical United States Compliance
UsernamePublicRestriction

Register

PS073498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By